EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. More Details
Adequate balance sheet and fair value.
Share Price & News
How has EyePoint Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EYPT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: EYPT's weekly volatility (8%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: EYPT underperformed the US Pharmaceuticals industry which returned 17.5% over the past year.
Return vs Market: EYPT underperformed the US Market which returned 35.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is EyePoint Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StEstimating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
5 months ago | Simply Wall StHow Many EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Do Institutions Own?
7 months ago | Simply Wall StIf You Had Bought EyePoint Pharmaceuticals' (NASDAQ:EYPT) Shares Five Years Ago You Would Be Down 86%
Is EyePoint Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EYPT ($8.22) is trading below our estimate of fair value ($84.12)
Significantly Below Fair Value: EYPT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: EYPT is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: EYPT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EYPT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EYPT is good value based on its PB Ratio (2x) compared to the US Pharmaceuticals industry average (2.9x).
How is EyePoint Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EYPT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EYPT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EYPT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EYPT's revenue (30.5% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: EYPT's revenue (30.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EYPT's Return on Equity is forecast to be high in 3 years time
How has EyePoint Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EYPT is currently unprofitable.
Growing Profit Margin: EYPT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EYPT is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.
Accelerating Growth: Unable to compare EYPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EYPT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.9%).
Return on Equity
High ROE: EYPT has a negative Return on Equity (-38.46%), as it is currently unprofitable.
How is EyePoint Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: EYPT's short term assets ($159.4M) exceed its short term liabilities ($13.4M).
Long Term Liabilities: EYPT's short term assets ($159.4M) exceed its long term liabilities ($58.0M).
Debt to Equity History and Analysis
Debt Level: EYPT's debt to equity ratio (32.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if EYPT's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EYPT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if EYPT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is EyePoint Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EYPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EYPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EYPT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EYPT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EYPT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Nancy Lurker (64 yo)
Ms. Nancy S. Lurker serves as a Member of Advisory Group at Novo Holdings A/S. She has been the Chief Executive Officer and President of EyePoint Pharmaceuticals, Inc. (formerly known as pSivida Corp.) sin...
CEO Compensation Analysis
Compensation vs Market: Nancy's total compensation ($USD2.10M) is above average for companies of similar size in the US market ($USD1.09M).
Compensation vs Earnings: Nancy's compensation has increased whilst the company is unprofitable.
Experienced Management: EYPT's management team is considered experienced (2.5 years average tenure).
Experienced Board: EYPT's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 130.4%.
EyePoint Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: EyePoint Pharmaceuticals, Inc.
- Ticker: EYPT
- Exchange: NasdaqGM
- Founded: 1987
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$236.255m
- Shares outstanding: 28.74m
- Website: https://eyepointpharma.com
Number of Employees
- EyePoint Pharmaceuticals, Inc.
- 480 Pleasant Street
- Suite B300
- United States
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/31 23:07|
|End of Day Share Price||2021/07/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.